GA NCORP

Treatment Sites

Northeast Georgia Medical Center - Gainesville

Nationally Ranked Cancer Services NGMC cares for more than 2,800 new cancer patients each year. That means our community has access to expert physicians, advanced cancer fighting technologies and some of the nation’s leading clinical trials. NGMC's Cancer Services are accredited with commendation by the American College of Surgeons Commission on Cancer (CoC)at the highest level of accreditation possible. NGMC is the only program in Georgia – and one of only 24 programs in the nation – to receive the 2018 Outstanding Achievement Award by the CoC.

Treatment Sites


Primary Location

NGMC-Gainesville
Wisteria Building Suite 420
200 South Enota
Gainesville, GA 30501
770-219-9010 (p)
770-219-7580 (f)
www.nghs.com

driving directions


Medical Plaza 1 Braselton

1515 River Place
Braselton, 30517
770-848-6070 (p)
www.nghs.com

driving directions


Toccoa Cancer Center

1640 Falls Rd.
Toccoa, 30577
706-297-7023 (p)
www.nghs.com

driving directions

Clinical Trials

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Cancer Type: Breast Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822


NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Cancer Type: Unspecified

Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
Cancer Type: Cervical Cancer

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy
Cancer Type: Cervical Cancer
Study Coordinator: Trena Davis BSN, RN, CRCC - 770-219-8822